• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Aptamer Extends Collaboration with AstraZeneca

    Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark

    Reed-Lane Facility Virtual Tour
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Data Management Trends

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Aptamer Extends Collaboration with AstraZeneca
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Emergent BioSolutions

    Syngene

    Adare Pharma Solutions

    PCI Pharma Services

    Cytovance Biologics
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Reed-Lane

    Aphena Pharma Solutions

    Cytovance Biologics

    Baxter BioPharma Solutions

    Almac Group
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Flex Your Outsourcing Model to Maximize Drug Development

    How to choose—and optimize—combinations of service models to fit your needs.

    Flex Your Outsourcing Model to Maximize Drug Development
    Related CONTENT
    • Covance Launches Laboratory Data Management Functional Service
    • Leveraging Machine Learning and AI in Clinical Research
    • Pricing Headwinds
    • Outsourcing in China: How far can it go?
    • Amgen, Novartis and Banner Discontinue CNP520 in AD
    Timothy King, Executive Director, Functional Service Partnerships (FSP), PPD09.16.19
    Strategically selecting the right outsourcing models can bend the cost and time curve of drug development by maximizing quality, operational success and financial efficiencies. But how do you identify the right service model—or even mix of models?

    A recent report on outsourcing from Tufts CSDD summarized data from numerous surveys and data sources since 2017 and concluded that outsourcing practices tend to be fragmented and tactical, inviting inefficiencies.1 The report found that clients often use a variety of outsourcing models, including transacting for individual tasks, functional/program service relationships and full-service relationships, but that only a third of companies believe these processes are well established and only a fifth rate them as “highly effective.”

    This article explores the rationale behind selecting one model versus another, the advantages and disadvantages of each and how clients can use data to evaluate the success of their model to drive more strategic outsourcing decision-making.

    To begin, we present below, an overview of the core models and the general pros and cons of each. Of note, to date, there is little industry consensus on these terms and descriptions, so, therefore, they vary widely among our customer base.

    Decision-making: Which model is best for me today?
    For many years, clients tended to embrace one model versus the other. That is, they kept everything “in-house” or they “relied completely on everything FSO.” Now we are seeing more flexibility in the outsourcing decision-making process and a greater blending of the various models.

    Therefore, what goes into the decision-making process when selecting which model to use? The first consideration is often historical precedent. We tend to trust what we know. Many organizations are simply designed to rely more on one model versus another.

    The second major consideration usually comes down to the level of internal resources and expertise. This can vary wildly from one drug, device, indication or even study versus another. For example, a client with significant internal knowledge and history about a therapeutic area or indication may turn to staff augmentation as an alternative to hiring internally. This drives fixed costs and carries the risk of layoffs down the road if, usually when, setbacks occur.

    A client who wants to supplement internal capacity by function versus by people (staff aug) may prefer FSP outsourcing arrangements, particularly for functions that are not seen as a differentiating, or core, competency. For example, clients rarely outsource the scientists driving preclinical research, but they may be happy to outsource site contracting, payment administration or statistical programming. FSP is graining traction as an outsourcing model as clients realize that by outsourcing individual functional services, they gain flexibility, volume discounts and efficiencies while retaining more control over what they consider their core competencies.

    Finally, a client who believes they have knowledge, experience and people-gaps on a study, especially if they are entering an indication that is new to them, are more likely to rely on FSO models.

    Today, clients are realizing they don’t have to choose one model over another, but that they can adopt hybrid approaches that mix and match features of staff aug, FSP and FSO within portfolios of studies to get the best of each model. The Tuft’s report validates this finding by reporting that 42%, 56% and 77% of clients reported “routinely using” staff aug, FSP, and FSO models, respectively.1 That “total” of 175% demonstrates that the models overlap for many organizations.

    A hybrid model offers the flexibility to create optimized, highly tailored solutions that may have the greatest impact on key operational metrics and deliverables. Even within a single client, different models may be preferred by region or country, functions, by phase of development or post-approval, by therapeutic areas, or even by asset.


    Table 1. Core features of outsourcing models.

    Use metrics to inform outsourcing decisions and drive process improvements
    Clients who use multiple and/or hybrid outsourcing models can compare key performance and quality indicators (KPIs, KQIs) across models. We find that these comparative data are the backbone of strategic selection of outsourcing models and process improvement. The data may support “doing it our way,” in either vendor or client systems and SOPs, or it may reveal areas where current processes are inefficient, increase audit findings or lead to expensive rework—or often, all three at the same time.

    Recently, we worked with a client who employed a hybrid outsourcing model on a portfolio of studies. Within this portfolio, we ran their FSO studies using one set of SOPs and templates for site contracting, and we worked on their insourced/FSP trials using a different set of SOPs with broader legal language fallback parameters and budget negotiation limits. With roughly 50 protocols in each model and comparative data generated starting in January 2016, the global average of contracting TATs (Turn Around Times) was reduced by 40 days when using the systems and SOPs within the FSP model. This example is not meant to illustrate the superiority of the FSP model, but rather to demonstrate that data stemming from two different models can cross inform each other to highlight areas of strength, as well as areas in need of process improvement.


    Table 2. Example metrics to track across outsourcing models.

    Conclusion
    The key is to be open to the insights that the data reveal and to be willing to challenge your thinking to strike the right balance. In truth, there is no optimal outsourcing model. Each delivers a set of pros and cons. The core need is to be agile and strategic enough to flex to meet the unique needs of different organizations and studies. As well, a hybrid approach, which offers the flexibility required to deliver time-efficient, high-quality services, while having transparency into the metrics to drive process improvement, may prove to be a good tool to keep in your tool kit.

    Examples of mixing multiple outsourcing strategies
     
    Client A: Studies are insourced in the countries where they have affiliates with a significant dependence on staff aug clinical research associates (CRAs), primarily using client systems and SOPs. Studies that are run mostly or entirely in countries without client affiliates are FSO.
     
    Client B: Metabolic studies are insourced using staff aug CRAs. Oncology studies use FSPs for data management and pharmacovigilance, using vendor systems/SOPs, while all other Phase II-III studies are FSO.
     
    Client C: Using a “hybrid FSO/FSP model,” a biotech client with FSO studies has certain key roles (project managers, CRAs, statisticians, medics, etc.) wrapped into a 100% dedicated (ring-fenced) FSP contract that spans multiple protocols in their portfolio.

    Reference
    1. Outsourcing outpaces internal spending but remains tactical and reactive. Tufts Center for the Study of Drug Development. Impact Report. March/April 2019.

    Timothy King, DrPH, MS, is an executive director for PPD FSP. In global medical research since 1990, Dr. King has built and led operational departments in a variety of therapeutic areas, including infectious diseases, hematology/oncology, cardiopulmonary and internal medicine. He also has worked on pharmacotherapies and medical devices, in both full-service and FSP models, with funding from industry, foundations and government agencies. He has a doctorate in public health and a master’s degree in epidemiology, both from the University of North Carolina.
    Related Searches
    • Preclinical
    • biotech
    • clinical research
    • Development
    Suggested For You
    Covance Launches Laboratory Data Management Functional Service Covance Launches Laboratory Data Management Functional Service
    Leveraging Machine Learning and AI in Clinical Research Leveraging Machine Learning and AI in Clinical Research
    Pricing Headwinds Pricing Headwinds
    Outsourcing in China: How far can it go? Outsourcing in China: How far can it go?
    Amgen, Novartis and Banner Discontinue CNP520 in AD Amgen, Novartis and Banner Discontinue CNP520 in AD
    Syneos Health Launches New FSP Model Syneos Health Launches New FSP Model
    Cytel and Axio Research Merge Cytel and Axio Research Merge
    Camargo to Acquire InSymbiosis Camargo to Acquire InSymbiosis
    Tergus to Build Commercial Manufacturing Facility Tergus to Build Commercial Manufacturing Facility
    Antares Vision Introduces Data Monitoring System Antares Vision Introduces Data Monitoring System
    Ebullient Bio CMOs Ebullient Bio CMOs
    Data Management in the Face of Growing Trial Complexity Data Management in the Face of Growing Trial Complexity
    Fibrocell, Castle Creek Enter Collaboration Fibrocell, Castle Creek Enter Collaboration
    Analytical CMC Outsourcing Analytical CMC Outsourcing
    Real World Evidence Developments Across the Globe Real World Evidence Developments Across the Globe

    Related Features

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20

    • Drug Development | Drug Discovery | R&D
      R&D Outsourcing Trends

      R&D Outsourcing Trends

      Highly specialized drug products and capacity needs drive increased reliance on contract service providers.
      Kristin Brooks, Managing Editor, Contract Pharma 10.14.20

    • Drug Development | Preclinical Outsourcing
      Preclinical Planning for Successful Drug Development

      Preclinical Planning for Successful Drug Development

      When the preclinical pressure is on, appropriate planning can make sure timelines are achievable.
      Mingyi Trimble, WuXi AppTec 09.09.20


    • APIs | Drug Development | Risk Management
      Small-Molecule Drug Development: Advantages of an Integrated, Phase-Based Approach

      Small-Molecule Drug Development: Advantages of an Integrated, Phase-Based Approach

      Small-molecule drug development has become more complex and challenging, leading to greater reliance on CDMOs.
      Sarah Bethune, Cambrex 09.09.20

    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Managing Editor 09.09.20

    • Drug Development | Regulatory Affairs
      Guidelines in Toxicology: A Blessing and a Curse

      Guidelines in Toxicology: A Blessing and a Curse

      A look at the evolution of drug development regulatory guides.
      Sarah Gould, Senior Principal Scientific Advisor, Charles River 09.16.19


    • Biologics, Proteins, Vaccines | Drug Delivery | Drug Development
      Knowledge Sharing: Biologics Development and Delivery

      Knowledge Sharing: Biologics Development and Delivery

      The increasing importance of sharing information to build awareness and better manage the complexities of drug development.
      Fran L. DeGrazio, Vice President of Scientific Affairs and Technical Services, West Pharmaceutical Services 09.16.19

    • Drug Development
      Improving Your Development Program

      Improving Your Development Program

      Seven lab science trends driving the future of drug development.
      Jenifer Vija, Liam Moran, Chris Loosbroock and Eric Snyder, Charles River 05.07.19

    • Drug Development
      Technical Advantages of Continuous Flow Chemical Synthesis

      Technical Advantages of Continuous Flow Chemical Synthesis

      Continuous flow chemistry is known for its ability to handle hazardous reactions safely, but can also unlock many other technological benefits.
      Shawn Conway, Engineering R&D Director, Cambrex High Point 04.05.19


    • Drug Development | Preclinical Outsourcing
      Early Development Trends

      Early Development Trends

      Catalent’s president of oral drug delivery, Jonathan Arnold, talks trends and challenges in the early phases of drug development.
      Tim Wright, Editor, Contract Pharma 03.06.19

    • Drug Development
      Future Trends in the CDMO Space

      Future Trends in the CDMO Space

      And how to navigate them for successful drug development
      Guillaume Plane, Global Development and Marketing Manager, BioReliance End-to-End Solutions, MilliporeSigma 01.25.19

    • APIs | Cytotoxics and High Potency Manufacturing | Drug Development
      CDMOs On The Rise

      CDMOs On The Rise

      Tracking growth and strategies in the CDMO business
      Michel Le Bars, Managing Partner, Kurmann Partners AGe 01.25.19


    • Drug Development | Formulation Development
      Abuse Deterrent Formulations

      Abuse Deterrent Formulations

      A look at opioid abuse in North America and formulations to help avoid an epidemic.
      Damon Smith, Richard Dart and Christopher Hirst 11.13.18

    • Drug Development
      Streamlining Drug Development:

      Streamlining Drug Development:

      Four key takeaways from Veeva’s 2018 R&D Summit
      Henry Levy, General Manager of Vault CDMS, Veeva Systems 11.13.18

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Haste Makes Waste

      Haste Makes Waste

      When to sprint and when to breathe in the race from lab to clinic.
      Christian Cattaruzza, MilliporeSigma 09.11.18

    Trending
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • Reed-Lane Facility Virtual Tour
    • Matica Biotechnology Breaks Ground On Cell And Gene Therapy Site
    • Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    Breaking News
    • AGC Biologics Expands Cell and Gene Facility in Italy
    • Celonic to Boost Cell & Gene Therapy Production
    • Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    • Aptamer Extends Collaboration with AstraZeneca
    • Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Thymoquinone Inhibits Viral Infection in In Vitro Settings, New Study Finds
    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Coatings World

    Latest Breaking News From Coatings World

    Sherwin-Williams Announces Resignation of President and COO
    Ashland Completes Expansion and Relocation of Viatel Bioresorbable Polymers Manufacturing Facility
    Evonik Receives Sustainability Award from EcVadis
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cretex CFO Announces Retirement
    New AI-Based Tool Developed for Coronary Artery Analysis, Intervention Planning
    First Reported Use of Pulse Biosciences' CellFX System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    AGC Biologics Expands Cell and Gene Facility in Italy
    Celonic to Boost Cell & Gene Therapy Production
    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Ulta Beauty Opens in Herald Square
    Elizabeth Arden Taps Sui He as Global Brand Ambassador
    Natura &Co Outperforms the Global Market in Q4 2020
    Happi

    Latest Breaking News From Happi

    What You're Reading on Happi.com
    Indie Beauty Innovators Wanted
    Cosmetic Chemists Seek Mentors
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Arjobex America welcomes Maggie Naberezny to sales team
    Henkel publishes 30th Sustainability Report
    Avery Dennison Smartrac launches new Circus Pro inlays
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Autefa Solutions Offers Fully Automated Line for Protective Mask Production
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Colfax Decides to Divide Its Businesses
    Stryker Corp.'s 2020 Sales Slip 3.6 Percent
    Bioventus Appoints Managing Director, China and Asia Pacific
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login